Cagrilintide
GLP-1 / metabolic · By Preptide Pro editorial team · Last updated
Cagrilintide is a glp-1 / metabolic peptide, and it is not FDA-approved. An investigational long-acting amylin analogue. Studied for weight management, alone and combined with semaglutide.
Not FDA-approvedChemistry (PubChem)
| PubChem CID | 171397054 |
|---|---|
| CAS number | 1415456-99-3 |
| Molecular formula | C194H312N54O59S2 |
| Molecular weight | 4409 g/mol |
| Other names | Cagrilintide, Cagrilintide [INN], RefChem:573322, GTPL13768, LDERDVMBIYGIOI-IZVMHKDJSA-N, EX-A10092, AT42613, analogue 23 [PMID: 34288673] |
Is Cagrilintide FDA-approved?
Not FDA-approved. No matching NDA or BLA was found in openFDA (Drugs@FDA).
How much research is there on Cagrilintide?
PubMed lists 107 records for “cagrilintide”, of which 15 are tagged as human clinical trials.
| Recent study | Journal | Date |
|---|---|---|
| Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy? | Lancet | 2026 Dec 20 |
| New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus. | Diabetes Ther | 2026 Nov |
| Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding. | Physiol Behav | 2026 Nov 1 |
| Continued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats. | Mol Metab | 2026 Oct 28 |
| Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose- and Comparator-Specific Systematic Review and Bayesian Meta-Analysis. | Diabetes Obes Metab | 2026 Oct 27 |
Sources
This is general research information, not medical advice. Check with a clinician before using any compound.